清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Abstract 14770: Reduction With Evolocumab in Complex Coronary Disease Requiring Revascularization: Insights From the FOURIER Trial

医学 传统PCI Evolocumab公司 血运重建 心脏病学 内科学 经皮冠状动脉介入治疗 支架 心肌梗塞 外科 载脂蛋白B 胆固醇 载脂蛋白A1
作者
Kazuma Oyama,Remo H M Furtado,Antônio Fagundes,Thomas A. Zelniker,Minao Tang,Julia Kuder,Sabina A. Murphy,Andrew Hamer,Huei Wang,Anthony Keech,Terje R. Pedersen,Robert P. Giugliano,Marc S. Sabatine,Brian Bergmark
出处
期刊:Circulation [Lippincott Williams & Wilkins]
卷期号:142 (Suppl_3) 被引量:3
标识
DOI:10.1161/circ.142.suppl_3.14770
摘要

Introduction: Although PCSK9 inhibitors induce plaque regression and reduce the risk of coronary revascularization overall, their ability to specifically reduce the risk of complex coronary atherosclerosis requiring revascularization has not been explored. Methods: FOURIER was a randomized trial of the PCSK9 inhibitor evolocumab vs. placebo in 27,564 patients with ASCVD on statin therapy (median achieved LDL-C 32 mg/dL vs. 89 mg/dL) followed for a median of 2.2 years. The study database was blindly reviewed to assess characteristics of coronary revascularization procedures. Complex revascularization was the composite of complex PCI (per GLOBAL LEADERS criteria, at least one of: multivessel PCI, 3 or more stents implanted, 3 or more lesions treated, bifurcation PCI with 2 or more stents, or total stent length >60 mm) or CABG. PCI complications included no-reflow, side branch loss, thrombus formation, major dissection, or perforation. The effects of evolocumab on types of revascularization and PCI complications were evaluated using Cox proportional hazards models. Results: 1724 patients underwent revascularization procedures during follow-up. Evolocumab reduced the risk of non-complex PCI by 22% (HR 0.78; 95%CI 0.70-0.88; P<0.001) and the risk of complex revascularization by 29% (HR 0.71; 95%CI 0.61-0.84; P<0.001), including complex PCI by 33% (HR 0.67; 95%CI 0.54-0.84; P<0.001) and CABG by 24% (HR 0.76; 95%CI 0.60-0.96; P=0.019; Figure). The incidence of reported PCI complications tended to be lower with evolocumab (HR 0.74; 95% CI 0.49-1.11). Conclusions: Adding evolocumab to statin therapy reduced the risk of developing complex coronary disease requiring revascularization, including complex PCI and CABG individually. Together with prior coronary imaging findings, these data suggest very aggressive LDL-C lowering to <1 mmol/L has beneficial effects on coronary atherosclerosis burden, anatomical complexity, and the need for intervention.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI2S应助科研通管家采纳,获得10
3秒前
3秒前
3秒前
12秒前
fabea完成签到,获得积分0
18秒前
寻梦发布了新的文献求助10
19秒前
明理绝悟完成签到 ,获得积分10
20秒前
小马甲应助寻梦采纳,获得10
29秒前
陈M雯完成签到 ,获得积分10
36秒前
junjie完成签到 ,获得积分10
38秒前
黑猫老师完成签到 ,获得积分10
51秒前
研友Bn完成签到,获得积分10
52秒前
Arctic完成签到 ,获得积分10
54秒前
ran完成签到 ,获得积分10
58秒前
guoxihan完成签到,获得积分10
1分钟前
king完成签到 ,获得积分10
1分钟前
青水完成签到 ,获得积分10
1分钟前
健忘青牛完成签到 ,获得积分10
1分钟前
长孙烙完成签到 ,获得积分10
1分钟前
汉堡包应助dadaup采纳,获得10
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
2分钟前
乐乐应助科研通管家采纳,获得10
2分钟前
艳艳宝完成签到 ,获得积分10
2分钟前
科研通AI6.2应助威威采纳,获得10
2分钟前
余如龙完成签到,获得积分10
2分钟前
2分钟前
赵芳完成签到,获得积分10
2分钟前
威威发布了新的文献求助10
2分钟前
timeless完成签到 ,获得积分10
2分钟前
ding应助Mason采纳,获得10
2分钟前
小黑猫跑酷完成签到 ,获得积分10
2分钟前
威威完成签到,获得积分10
2分钟前
YNILY完成签到 ,获得积分10
3分钟前
煲汤的螃蟹完成签到 ,获得积分10
3分钟前
yindi1991完成签到 ,获得积分10
3分钟前
3分钟前
zw完成签到,获得积分10
3分钟前
Mason发布了新的文献求助10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
PowerCascade: A Synthetic Dataset for Cascading Failure Analysis in Power Systems 2000
Picture this! Including first nations fiction picture books in school library collections 1000
Signals, Systems, and Signal Processing 610
Unlocking Chemical Thinking: Reimagining Chemistry Teaching and Learning 555
Photodetectors: From Ultraviolet to Infrared 500
Cancer Targets: Novel Therapies and Emerging Research Directions (Part 1) 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6358906
求助须知:如何正确求助?哪些是违规求助? 8172953
关于积分的说明 17211416
捐赠科研通 5413894
什么是DOI,文献DOI怎么找? 2865319
邀请新用户注册赠送积分活动 1842737
关于科研通互助平台的介绍 1690806